Invitrogen™ CD161 Monoclonal Antibody (HP-3G10), APC, eBioscience™

Beskrivning

Description: This HP-3G10 monoclonal antibody reacts with CD161 (also known as NKR-P1A), a member of the C-type lectin superfamily. The human homologue of NK1.1 in C57BL/6 mice, CD161 is expressed on natural killer cells and is upregulated in response to IL-12. CD161 can also be detected on various T cell subsets, including memory/effector CD4+ T cells, CD8+ T cells, gamma delta TCR T cells, and a subset of CD3+ thymocytes. Finally, CD161 expression has been demonstrated on human Th17 CD4+ T cells. The function of this receptor is unclear although studies suggest a possible stimulatory role. Nevertheless, Lectin-like transcript-1 (LLT1), which is also known as osteoclast inhibitory lectin, has been identified as the ligand for CD161. Applications Reported: This HP-3G10 antibody has been reported for use in flow cytometric analysis. Applications Tested: This HP-3G10 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 μL (0.25 μg) per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser. Filtration: 0.2 μm post-manufacturing filtered.

KLRB1 (Killer cell lectin like receptor subfamily B, member 1, CD-161) protein is classified as a type II membrane protein because it has an external C terminus. KLRB1 cell surface antigen is expressed by almost all NK cells and in a small subset of CD3+ve T cells. KLRB1 is a homodimeric cell surface protein, comprising two chains with molecular weights ranging from 40-44kDa. KLRB1 plays an inhibitory role on natural killer (NK) cells. Activation of KLRB1 leads to acid sphingomyelnase/SMPD1 stimulation and an increase in intracellular ceramide. Moreover, there is also an activation of AKT1/PKB and RPS6KA1/RSK1 kinase stimulation, and T cell proliferation by anti-CD3. KLRB1 acts as a lectin that binds to the terminal carbohydrate Gal-alpha(1,3)Gal epitope and to the N-acetyllactosamine epitope. KLRB1 also binds to CLEC2D/LLT1 as a ligand, and inhibits NK cell-mediated cytotoxicity as well as interferon-gamma secretion in target cells. The KLRB1 protein contains an extracellular domain with several motifs characteristic of C-type lectins, a transmembrane domain, and a cytoplasmic domain.